Pablo Ortiz, MD, PhD, of the University Hospital 12 of October, Madrid, Spain, speaks at the European Organisation for the…
Browsing: Non-Hodgkin Lymphoma
Pablo Ortiz, MD, PhD, of the University Hospital 12 of October, Madrid, Spain, speaks at the European Organisation for the…
Michael Khodadoust, MD, PhD, of the Stanford University School of Medicine, Stanford, CA, discusses the future of checkpoint inhibitors in…
Michael Khodadoust, MD, PhD, of the Stanford University School of Medicine, Stanford, CA, speaks at the European Organisation for the…
Topical alkylating agents have proven beneficial in treating patients with mycosis fungoides (MF). Here, Martine Bagot, MD, PhD, of Saint…
Martine Bagot, MD, PhD, of Saint Louis Hospital, Paris, France, discusses the exciting new approval of the antibody mogumulizumab for…
Martine Bagot, MD, PhD, of Saint Louis Hospital, Paris, France, speaks at the European Organisation for the Research and Treatment…
An accurate and optimized clinical scoring system is essential for the staging and management of cutaneous T-cell lymphoma. Here, Pietro…
CD47 has been found to be present on leukemic stem cells, but not on normal hematopoietic stem cells, offering an…
From the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2018 meeting held in Nice, France, Francine Foss, MD, of Yale University…
Cell-based therapies are an exciting area across the board in oncology. Here, our experts discuss the use of cellular therapy…
Viruses such Epstein-Barr virus (EBV) and HIV have been aetiologically linked to a significant number of lymphoproliferative diseases. In this…
While mantle cell lymphoma (MCL) can be an aggressive disease, there is a subgroup of patients whose disease poses low…
The International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2018 meeting held in Nice, France, presented an array of exciting new data…
Here, John Gribben, MD, DSc, FRCP, FRCPath, FMed Sci, of Barts Cancer Institute, London, UK, chairs a discussion with Anas…
Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Simon Rule, MD, from Plymouth University,…
Providing us with insight into a trial not yet published, Pierluigi Porcu, MD, from Jefferson Hospital, Sidney Kimmel Cancer Center,…
Speaking at the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Nathan Fowler, MD, of The University…
The discovery of mutational events in cancer are crucial to the development of efficacious targeted therapies. Here, Steven Treon, MD,…
Although there is a lot known about Waldenströms macroglobulinemia (WM), there is little understanding of the wild-type and IgM-related disorders.…
The therapeutic potential for Waldenströms macroglobulinemia (WM) is widening, with our growing understanding and knowledge of the genetics behind this…
Pierluigi Porcu, MD, Thomas Jefferson University, shares Find Better Predictive Biomarkers for Response | Expand Data to Other of T-Cell…
Pierluigi Porcu, MD, Thomas Jefferson University talks about a Huge Need for Better Therapy for CTCL | Hope for FDA-Approval…
Pierluigi Porcu, MD, Thomas Jefferson University explains Compliance of MAVERICK Dataset was 95%-96%| Analysis Based on Longitudinal Assessment at Annual…
Pierluigi Porcu, MD, Thomas Jefferson University explains Efficacy Moga, Room for Improvement | In Terms of Response Rate & Progression-free…
Pierluigi Porcu, MD, Thomas Jefferson University explains Quality-of-Life Data for MAVERICK Study | Using 2 Specific Tools for CTCL Had…
Ana Limon Carrera, Takeda Oncology, Mechanism of Action Molecule – Pevonedistat | Based on Protein Homeostasis Developed by Takeda at…
Jon Eckard, PhD, TYME Inc., explains Development in Solid & Liquid Tumor Front Complete & partial response in Hodgkins, Non-Hodgkins…
Dr. Meletios A. Dimopoulos, MD, National and Kapodistrian University of Athens, explains Waldenstrom Macroglobulinemia is Rare Disease Results of study…
Dr. Meletios A. Dimopoulos, MD, National and Kapodistrian University of Athens, talks about Better Defining Nature of Mutations of Genes…
Dr. Meletios A. Dimopoulos, MD, National and Kapodistrian University of Athens, explains Acalabrutinib is Another BTK Inhibitor Active drug for…
Dr. Meletios A. Dimopoulos, MD, National and Kapodistrian University of Athens, talks about Devising Future Trials That Add Another Agent…